Recalls & Warnings September 07, 2002 FDA Sends Warning Letters to Seven Online Supplement Sellers For Therapeutic Claims On August 27, 2002, the FDA posted seven "Cyber" letters recently issued from its Center for Food Safety and Applied Nutrition (CFSAN) to internet website operators promoting dietary supplement products that claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of
The primary interaction concern is with oral medications that depend on consistent absorption
doi: 10.1007/s00384-012-1632-2
Hanioka, N., Jinno, H., Nishimura, T., and Ando, M
Anti-Aging Support As a strong antioxidant, glutathione helps protect skin from environmental damage that contributes to early aging
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
